Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall.^[3] In September 2011 Alkermes, Inc. merged with Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan Corporation, plc.^[4] The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and manufacturing facilities in Athlone, Ireland, and Wilmington, Ohio.^[1]

Quick Facts Company type, Traded as ...

Alkermes plc

Company type	Public
Traded as	Nasdaq: ALKS S&P 600 component
Industry	Biotechnology
Founded	1987; 37 years ago (1987)
Founder	Michael Wall
Headquarters	Dublin , Ireland[1]
Key people	Richard Pops (CEO)
Revenue	US$1.1 billion (2022)[2]
Operating income	US$-20.5 million
Net income	US$-158 million (2022)
Total assets	US$1.9 billion
Total equity	US$1 billion
Number of employees	2,100
Website	www.alkermes.com

Close

Alkermes has four proprietary commercial drug products^[5] approved for the treatment of schizophrenia, bipolar I disorder, alcohol dependence and opioid dependence. These include olanzapine and samidorphan (Lybalvi), an atypical antipsychotic and opioid modulator combination intended for the treatment of schizophrenia and bipolar I disorder; aripiprazole lauroxil (Aristada), a long-acting injectable for schizophrenia; and naltrexone for extended-release injectable suspension (Vivitrol) for alcohol and opioid dependence.

Other products utilizing Alkermes' proprietary technologies include: diroximel fumarate (Vumerity) for multiple sclerosis, risperidone (microspheres) long-acting injectable (Risperdal Consta) for schizophrenia and bipolar I disorder, paliperidone palmitate (Invega Sustenna, Invega Trinza and Invega Hafyerain in the U.S., Xeplion, Trevicta and Bynnali in Europe) for schizophrenia.^[6][7]

In October 2023, Alkermes announced its first data related to its orexin 2 receptor (OXR2) agonist, ALKS 2680. ALKS 2680 is in development for the treatment of narcolepsy.^[8]

In November 2023, Alkermes completed the planned separation of its oncology business into a new company, Mural Oncology, which plans to continue to work on the investigational interleukin-2 (IL-2) drug, nemvaleukin alfa.^[9]